Cough Assist Devices Market Revenue to Cross USD 480 Mn by 2031 | TMR Study
April 06, 2023 14:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, April 07, 2023 (GLOBE NEWSWIRE) -- The global cough assist devices market size was worth USD 218.5 Mn in 2021 and is expected to exceed value of USD 480.7 Mn by...
DirectRx Specialty Pharmacy Pledges Support to the COPD Foundation as a Corporate Social Responsibility Partner
March 16, 2023 12:06 ET
|
DirectRx Pharmacy
TROY, Mich., March 16, 2023 (GLOBE NEWSWIRE) -- DirectRx, a leading national specialty pharmacy dedicated to serving individual patients with complex and chronic health needs, today announced it has...
$179.34 Million by 2028, OPEP (Oscillating Positive Expiratory Pressure) Devices Market, 5.2% CAGR Lead by Mouthpiece PEP Devices - Exclusive Research Report by The Insight Partners
May 10, 2022 04:13 ET
|
The Insight Partners
New York, May 10, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Oscillating Positive Expiratory Pressure (OPEP) Devices Market Forecast to 2028 – COVID-19 Impact...
Raptor Pharmaceutical to Hold Second Quarter 2016 Financial Results Conference Call and Webcast on Thursday, August 4, 2016, at 4:30 p.m. EDT
July 28, 2016 07:30 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., July 28, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the company will release second quarter 2016 financial results on Thursday, August 4,...
Raptor Pharmaceutical to Participate in the 2016 JMP Life Sciences Conference
June 14, 2016 07:30 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., June 14, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it will participate in the following investor conference:Julie Anne Smith, President...
Raptor’s PROCYSBI® New Drug Submission Accepted by Health Canada with Priority Review
March 21, 2016 16:05 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., March 21, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that Health Canada has accepted for review its New Drug Submission (NDS) for PROCYSBI®...
Raptor Announces Qualified Infectious Disease Product (QIDP) Designation for MP-376, Inhaled Levofloxacin
March 16, 2016 07:30 ET
|
Raptor Pharmaceutical Inc
Granted for Three Distinct Indications: Chronic Pulmonary Infections Due to Pseudomonas Aeruginosa in Patients with Cystic Fibrosis and in Patients with Non-Cystic Fibrosis Bronchiectasis as...
Raptor Pharmaceutical Corp. Reports Fourth Quarter and Full Year 2015 Financial Results and Provides 2016 Corporate Update
February 25, 2016 16:05 ET
|
Raptor Pharmaceutical Inc
2015 Global Net Revenue for PROCYSBI® of $94.2 Million Reported 2016 Global Net Revenue Guidance of $115 to $125 Million 2016 Anticipated PROCYSBI Growth of 25%-30% Year-Over Year Company to Host...
Raptor Pharmaceutical to Hold Fourth Quarter and Full Year 2015 Financial Results Conference Call and Webcast on Thursday, February 25, 2016, at 4:30 p.m. ET
February 18, 2016 07:30 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Feb. 18, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the company will release fourth quarter and full year 2015 financial results on...
Raptor Pharmaceutical Completes Acquisition of Quinsair(TM)
October 05, 2015 07:05 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Oct. 5, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it has completed the acquisition of Quinsair™ (levofloxacin inhalation solution)...